TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control Study.
COVID-19
Rheumatoid arthritis
Seronegative spondyloarthropathies
TNF-α blockers
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
05
03
2021
accepted:
23
06
2021
pubmed:
24
7
2021
medline:
24
7
2021
entrez:
23
7
2021
Statut:
ppublish
Résumé
The interaction between angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 is a crucial factor in the viral infections leading to the release of inflammatory proteins, such as TNF-α. Thus, it is hypothesized that TNF-α blockers can prevent either COVID-19 incidence or its serious symptoms. TNF-α blockers are prescribed to treat various autoimmune disorders, including rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA). Therefore, the objective of this work was to examine this hypothesis that TNF-α blockers can prevent COVID-19 incidence in patients with RA or SpA. A case-control study was conducted through interviews based on a structured questionnaire to investigate the frequency of COVID-19 incidence in 254 eligible patients with RA or SpA about whom 45% were under treatment with one type of TNF-α blockers including infliximab, adalimumab, and etanercept at least for 3 months during the COVID-19 pandemic. Interviews were carried out twice, at the beginning and the end of the study (June-December 2020). Patients with COVID-19 during the study or before that were considered as cases. The control group was patients without COVID-19 experience. Data were analyzed using descriptive statistics, and logistic regression was used to determine the relationships between COVID-19 incidence and independent variables. A small percentage of patients treated with TNF-α blockers (5.22%, 6/115) experienced COVID-19, while a large percentage of patients with COVID-19 did not receive TNF-α blockers (27.34%, 38/139). According to odds ratio, adalimumab, infliximab, and etanercept decreased significantly the risk of developing COVID-19 up to 96.8, 95, and 80.3% (p < 0.05), respectively. Therefore, TNF-α blockers could probably decrease the chances of the COVID-19 incidence in patients with RA or SpA. A direct and positive correlation between the use of TNF-α blockers and a reduction in the incidence of COVID-19 could suggest the prophylactic role of these drugs in preventing COVID-19 in patients with RA and SpA.
Identifiants
pubmed: 34297311
doi: 10.1007/s40744-021-00342-8
pii: 10.1007/s40744-021-00342-8
pmc: PMC8299175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1355-1370Subventions
Organisme : Isfahan University of Medical Sciences
ID : 199119
Informations de copyright
© 2021. The Author(s).
Références
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
doi: 10.1007/978-1-4939-2438-7_1
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–92.
doi: 10.1038/s41579-018-0118-9
Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and SARS-CoV-2. Turk J Med Sci. 2020;50(SI-1):549–56.
doi: 10.3906/sag-2004-127
Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020;94:44–8.
doi: 10.1016/j.ijid.2020.03.004
Kuhn J, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci. 2004;61(21):2738–43.
doi: 10.1007/s00018-004-4242-5
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.
doi: 10.1038/nature02145
Zipeto D, da Palmeira JF, Argañaraz GA, Argañaraz ER. ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19. Front Immunol. 2020;11: 576745.
doi: 10.3389/fimmu.2020.576745
Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert A protective effect on COVID-19. Nephrol Dial Transplant. 2020;35(6):1071–2.
doi: 10.1093/ndt/gfaa093
Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4(2):247–61.
doi: 10.1007/s40744-017-0073-3
Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217.
doi: 10.1038/nrrheum.2017.22
Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-Α blockers. Curr Neurol Neurosci Rep. 2017;17(4):36.
doi: 10.1007/s11910-017-0742-1
Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review. Int J Rheum Dis. 2016;19(6):536–50.
doi: 10.1111/1756-185X.12659
Shale M, Czub M, Kaplan GG, Panaccione R, Ghosh S. Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Ther Adv Gastroenterol. 2010;3(3):173–7.
doi: 10.1177/1756283X10366368
Barbara JA, Van Ostade X, Lopez AF. Tumour necrosis factor-alpha (TNF-Α): the good, the bad and potentially very effective. Immunol Cell Biol. 1996;74(5):434–43.
doi: 10.1038/icb.1996.73
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.
doi: 10.1128/MMBR.05015-11
Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39:2085–94.
doi: 10.1007/s10067-020-05190-5
Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11(1):3774. https://doi.org/10.1038/S41467-020-17703-6 .
doi: 10.1038/S41467-020-17703-6
pubmed: 32709909
pmcid: 7382482
Tursi A, Vetrone LM, Papa A. Anti-TNF-Α agents in inflammatory bowel disease and course of COVID-19. Inflamm Bowel Dis. 2020;26(7):E73.
doi: 10.1093/ibd/izaa114
Migkos MP, Kaltsonoudis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A, et al. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int. 2021;41(5):903–9. https://doi.org/10.1007/S00296-021-04818-2 .
doi: 10.1007/S00296-021-04818-2
pubmed: 33655421
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Ann Rheum Dis. 2020;79(7):859–66.
doi: 10.1136/annrheumdis-2020-217871
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Ann Rheum Dis. 2021. https://doi.org/10.1136/Annrheumdis-2020-219498 .
doi: 10.1136/Annrheumdis-2020-219498
pubmed: 34321218
Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):175–80.
pubmed: 32207680
Clark IA. Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm. Rev Med Virol. 2020;24:e2210.
Robinson PC, Richards D, Tanner HL, Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2(11):E653–5. https://doi.org/10.1016/S2665-9913(20)30309-X .
doi: 10.1016/S2665-9913(20)30309-X
pubmed: 33521660
pmcid: 7832144
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020;383(1):85–8. https://doi.org/10.1056/Nejmc2009567 .
doi: 10.1056/Nejmc2009567
pubmed: 32348641
Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):1–10.
doi: 10.1186/s13054-019-2683-3
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course Of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–8. https://doi.org/10.1136/Annrheumdis-2020-217424 .
doi: 10.1136/Annrheumdis-2020-217424
pubmed: 32241793
Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis. 2020;79(9):1251–2. https://doi.org/10.1136/Annrheumdis-2020-217362 .
doi: 10.1136/Annrheumdis-2020-217362
pubmed: 32354772
Murdaca G, Colombo B, Puppo F. Anti-TNF-Α inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22(3):557–65.
doi: 10.1177/039463200902200301
Schultheiss JPD, Brand EC, Lamers E, Van Den Berg WCM, Van Schaik FDM, Oldenburg B, et al. Earlier discontinuation Of TNF-Α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Aliment Pharmacol Ther. 2019;50(4):386–96. https://doi.org/10.1111/Apt.15380 .
doi: 10.1111/Apt.15380
pubmed: 31310690
Klein SL, Morgan R. The impact of sex and gender on immunotherapy outcomes. Biol Sex Differ. 2020;11(1):24. https://doi.org/10.1186/S13293-020-00301-Y .
doi: 10.1186/S13293-020-00301-Y
pubmed: 32366281
pmcid: 7197158
Sama IE, Voors AA. Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome? Eur Heart J. 2020;41(32):3096. https://doi.org/10.1093/Eurheartj/Ehaa526 .
doi: 10.1093/Eurheartj/Ehaa526
pubmed: 32577762
pmcid: 7337767
Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020;157: 104833. https://doi.org/10.1016/J.Phrs.2020.104833 .
doi: 10.1016/J.Phrs.2020.104833
pubmed: 32302706
pmcid: 7194807
Frohman EM, Cruz RA, Longmuir R, Steinman L, Zamvil SS, Villemarette-Pittman NR, et al. Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: an immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack. J Neurol Sci. 2020;415: 116935.
doi: 10.1016/j.jns.2020.116935
Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci. 2020;415: 116942.
doi: 10.1016/j.jns.2020.116942
Rodenburg RJ, Ganga A, Van Lent PL, Van De Putte LB, Van Venrooij WJ. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor Α expression in macrophages by inducing apoptosis. Arthritis Rheum. 2000;43(9):1941–50.
doi: 10.1002/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O
Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71–2. https://doi.org/10.1038/S41584-020-00562-2 .
doi: 10.1038/S41584-020-00562-2
pubmed: 33339986
Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-rheumatic drugs for the fight against the novel coronavirus infection (Sarscov-2): what is the evidence? Mediterr J Rheumatol. 2020;31(Suppl 2):259–67. https://doi.org/10.31138/Mjr.31.3.259 .
doi: 10.31138/Mjr.31.3.259
pubmed: 33196003
pmcid: 7656133
Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol. 2020;72(12):1981–9. https://doi.org/10.1002/Art.41456 .
doi: 10.1002/Art.41456
pubmed: 32725762